PRIMARY STUDY
Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis
Key Findings: Cannabidiol is associated with clinical improvement in children with Dravet syndrome. However, it was also associated with decreased appetite, and possibly adverse mental events.
Type of Study: Meta-analysis
Study Sample Size: 8
Study Result: Positive
Research Location(s): Belgium, Israel, Netherlands
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD), Cannabinoid (unspecified), Pharma THC, Pharma THC:CBD, Pharma CBD, Tetrahydrocannabivarin (THCV)
Phytocannabinoid Source: Not Applicable
DOSING DETAILS 
Study Dosing Objective: Effective Dose, Safety Profile
Established Protocol: Effective dose with adverse effects
Cannabinoid Ratio: (Pharma CBD : Pharma THC : Pharma THC:CBD) 0 : 0 : 0 
Clinical Relevance: Cannabidiol is associated with a 50% reduction in seizure rate, clinical improvement in Dravat syndrome, and caregiver global impression of change, but may also reduce appetite.
Adverse Events: 20 mg/kg/d CBD results in a significant, elevated risk for decreased appetite 10 mg/kg/d might result in a mild elevation in the risk
Citation: Treves N, et al. Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis. Sci Rep. 2021; 11:23462. doi: 10.1038/s41598-021-02770-6
Authors: Treves N, Mor N, Allegaert K, Bassalov H, Berkovitch M, Stolar OE, Matok I
